Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab

NCT03414658 is registered in ClinicalTrials.gov with Adrienne G. Waks as lead sponsor.

NCT NCT03414658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03414658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab
Lead sponsor
Adrienne G. Waks
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 21, 2018
Completion date
May 31, 2027
Enrollment
100 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer